Ted W. Johnson

机构：Pfizer (United States) · ORCID：0000-0002-3541-9747

发表论文 82 篇 · 总被引 5384 次 · h-index 28

代表论文

• Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission (2022 · Nature · 被引 527)
• Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer (2022 · Nature Cancer · 被引 73)
• Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1 (2023 · Journal of Medicinal Chemistry · 被引 40)
• Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer (2024 · Journal of Medicinal Chemistry · 被引 23)
• Wastewater sequencing uncovers early, cryptic SARS-CoV-2 variant transmission (2021 · medRxiv · 被引 23)
• LTK fusions: A new target emerges in non-small cell lung cancer (2022 · Cancer Cell · 被引 20)